Avance Clinical Recognized As Finalist In 62nd Australian Export Awards For International Health

Avance Clinical, a leading Australian Contract Research Organization (CRO), has been named a finalist in the prestigious 62nd Australian Export Awards, under the International Health category. This recognition highlights the company’s exceptional contributions to the global biotechnology sector, supported by its reputation for delivering high-quality data, fast clinical trial timelines, and innovative clinical trial solutions.

CEO Yvonne Lungershausen will represent Avance Clinical at the awards ceremony, accompanied by Liahna Toy, Vice President, Commercial Business Development. The nomination reflects Avance Clinical’s strong growth and its commitment to empowering biotechnology companies globally through world-class clinical trial services.

“This recognition is a testament to the dedication and expertise of our team,” said Lungershausen. “We are proud to support innovative therapies addressing areas of unmet medical need, across more than 250 indications in EARLY PHASE studies, and particularly in oncology, rare diseases, infectious diseases, and central nervous system disorders. Being named a finalist celebrates our global impact and our mission to improve health outcomes for patients.”

Supporting Biotech Success Globally

Avance Clinical’s expertise spans the full clinical development lifecycle, from consulting on pre-clinical strategy to execution of clinical trials. The company has earned a reputation for delivering quality, globally accepted clinical data while helping biotech companies navigate complex regulatory environments.

By combining local knowledge with a global perspective, Avance Clinical has positioned itself as a trusted partner for biotechnology companies. Its extensive site network across Australia, New Zealand, Asia, and North America, enables seamless trial execution and a streamlined path to market for biotech innovations.

A Legacy of Excellence

This finalist nomination follows Avance Clinical’s success at the 2024 Premier’s Business and Export Awards in South Australia, where the company was honored as the International Health Exporter of the Year. Over the past year, the company has continued to grow its operations, expand its partnerships, and deliver innovative solutions that meet the rigorous standards of global regulatory authorities such as the FDA and EMA.

“Our focus has always been on partnering with biotechs to ensure their success in bringing life-changing therapies to patients,” Lungershausen said. “This recognition reflects the strength of our approach and the exceptional work of our global team.”

Looking to the Future

The 62nd Australian Export Awards celebrate Australian businesses excelling in international trade. For Avance Clinical, this acknowledgment is not just a celebration of its achievements but also a milestone in its mission to remain at the forefront of clinical trial innovation.

“We’re honoured to represent Australia’s clinical trial industry on this stage and look forward to continuing our legacy of innovation and excellence.”

Avance Clinical’s place among the finalists underscores its growing influence as a leading global CRO for biotechs, dedicated to delivering results that accelerate drug development and improve patient outcomes.

Discover the complete list of finalists here.